On the interference of sildenafil on platelet aggregation: An ex vivo pilot study
IJC Metabolic & Endocrine · 2014
DOI: 10.1016/j.ijcme.2014.07.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift IJC Metabolic & Endocrine, 2014. Verfasst von Lucrezia Gambardella und 5 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).
Abstract (Originalsprache)
Fig. 1. Platelet aggregation determined in the whole blood by using a Multiplate aggregometer in response to 6.5 μM ADP (A) and 3.2 μg/ml collagen (B). Tests were performed in duplicate determinations. D1 indicates donors with high platelet reactivity; D2 indicates donors with low platelet reactivity. The values are expressed in arbitrary aggregation units (AU). For ADP: *p = 0.009; **p = 0.001; ***p = 0.0007. For collagen: °p = 0.01; °°p = 0.003; °°°p = 0.001. Sildenafil citrate is a potent vasodilating agent mainly used for erectile dysfunction [1]. In the recent years, its use has also become more popular among men without erectile dysfunction to enhance sexual performance [2]. In addition, although not included in the WADA (World Anti-Doping Agency) prohibited list, the increasing incidence of its use among young athletes has drawn the attention of the antidoping authorities, who recognized its potential use associated with steroid doping (http://www.realchampion.jp/assets/uploads/2013/03/ 2010_ProhibitedList). The drug is a selective inhibitor of phosphodiesterase type 5 (PDE-5) that increases the action of nitric oxide by preventing the hydrolysis of cyclic guanosine monophosphate. PDE-5 is located not only in the corpus cavernosum (the main target of this drug) but also, in other cells, including vessel cells and circulating cells [3]. Accordingly, evidence from clinical trials and experimental studies suggested that sildenafil could exert a plethora of pharmacological beneficial actions in different clinical matters [4]. For instance, in patients with pulmonary arterial hypertension sildenafil improves pulmonary exercise capacity and quality of life by increasing the supply of blood to the lungs. Furthermore, it has been shown that sildenafil has a potential therapeutic efficacy for disorders related to the central nervous system. It exerts neuro-protective effects in multiple sclerosis and has a significant memory enhancing action [4]. However, unfortunately, some adverse effect of the drug has also been reported. Acute myocardial infarction, sudden cardiac death, symptomatic non-fatal ventricular arrhythmia, transient cerebral ischemic attacks, and hemorrhagic stroke have been documented in patients engaging in sexual exertion assisted with the use of sildenafil [5,6]. Since platelet hyperactivity may cause thrombotic disorders [7] whereas their hypo-aggregation can lead to hemorrhagic disorders [8] in the present work we decided to evaluate the ex vivo effects of sildenafil on platelet aggregation pattern in a small cohort of young and healthy individuals (HD). Twenty non-smokers HDmen, aged between 20 and 40 years have been recruited at the Institute of Hematology, University “La Sapienza” of Rome. The nature and purpose of the study were explained to all participants who gave their informed consent following the rules of good medical practice.
Zitieren
APA
Gambardella, L., Lista, P., Pichini, S., Pacifici, R., Malorni, W., & Straface, E. (2014). On the interference of sildenafil on platelet aggregation: An ex vivo pilot study. IJC Metabolic & Endocrine. https://doi.org/10.1016/j.ijcme.2014.07.005
Vancouver
Gambardella L, Lista P, Pichini S, Pacifici R, Malorni W, Straface E. On the interference of sildenafil on platelet aggregation: An ex vivo pilot study. IJC Metabolic & Endocrine. 2014. doi:10.1016/j.ijcme.2014.07.005
BibTeX
@article{Gambardella2014,
author = {Gambardella, Lucrezia and Lista, Pasquale and Pichini, Simona and Pacifici, Roberta and Malorni, Walter and Straface, Elisabetta},
title = {On the interference of sildenafil on platelet aggregation: An ex vivo pilot study},
journal = {IJC Metabolic & Endocrine},
year = {2014},
doi = {10.1016/j.ijcme.2014.07.005}
}
EUVIMED